Report Overview

The US Atopic Dermatitis drugs market size stood at USD 2.7 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Atopic dermatitis (AD) is the most common type of eczema, affecting a large percentage of worlds population. Although atopic dermatitis can occur at any age, the disease mostly affects infants and children, and subsides with age. Increasing prevalence of AD is the primary growth stimulant for the market.

Exact cause of the condition is unknown; however, the disease is speculated to result from a combination of environmental and genetic factors. AD affects males and females equally. Approximately 60.0% patients with AD develop symptoms in the first year and roughly 90.0% patients show symptoms by the age of five (atopic march). Disease onset after the age of 30 is rare and may be caused by exposure to harsh environmental conditions.



Market Drivers

Rise in awareness regarding the availability of treatments for the disease has helped the market gain traction over the past few years. Initiatives undertaken by governments to provide better and more affordable treatment and the presence of favorable reimbursement policies are likely to provide an upthrust to the market. Furthermore, growing acceptance of targeted therapies such as Eucrisa and Dupixent is also working in favour of the market.

High cost of therapeutics is one of the key roadblocks in the upward climb of the market. However, affordable healthcare measures are being incorporated across all major regions, impacting pricing strategies of companies as well as reimbursement scenarios. Heightened cost consciousness, especially in emerging countries, is anticipated to hinder premium-pricing opportunities for upcoming AD drugs, particularly biologics.